MIM
NBIX icon

Macroview Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Macroview Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-97
Closed -$11.2K – 366
2024
Q3 		$11.2K Buy
97
+74
+322% +$10.1K 0.01% 220
2024
Q2 		$3.17K Hold
23
– – ﹤0.01% 427
2024
Q1 		$3.17K Hold
23
– – ﹤0.01% 467
2023
Q4 		$3.03K Sell
23
-73
-76% -$8.4K ﹤0.01% 457
2023
Q3 		$10.8K Buy
96
+88
+1,100% +$9.27K 0.01% 238
2023
Q2 		$755 Hold
8
– – ﹤0.01% 434
2023
Q1 		$810 Sell
8
-105
-93% -$10.9K ﹤0.01% 389
2022
Q4 		$13.5K Hold
113
– – 0.02% 159
2022
Q3 		$12K Buy
113
+105
+1,313% +$10.7K 0.02% 147
2022
Q2 		$1K Hold
8
– – ﹤0.01% 405
2022
Q1 		$1K Hold
8
– – ﹤0.01% 391
2021
Q4 		$1K Hold
8
– – ﹤0.01% 359
2021
Q3 		$1K Hold
8
– – ﹤0.01% 349
2021
Q2 		$1K Hold
8
– – ﹤0.01% 375
2021
Q1 		$1K Hold
8
– – ﹤0.01% 349
2020
Q4 		$1K Hold
8
– – ﹤0.01% 324
2020
Q3 		$1K Buy
+8
New +$925 ﹤0.01% 299
2019
Q4 		– Sell
-37
Closed -$3K – 325
2019
Q3 		$3K Buy
+37
New +$3.46K 0.01% 237

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Macroview Investment Management's NBIX Position: Q4 2024 in Review

Macroview Investment Management sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 97 shares — an estimated $11.2K sold.

Macroview Investment Management first reported a position in NBIX in Q3 2019 and held it in 18 quarters. The position peaked at $13.5K in Q4 2022. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Macroview Investment Management reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Macroview Investment Management sold 97 Neurocrine Biosciences shares in Q4 2024, an estimated $11.2K.
  • Macroview Investment Management first reported a position in Neurocrine Biosciences in Q3 2019 and held it in 18 quarters.
  • Macroview Investment Management's Neurocrine Biosciences position peaked at $13.5K in Q4 2022.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Macroview Investment Management's 13F filing for Q4 2024, filed 31 Jan 2025.